

**McCreadie Group, Inc.**

**NEWS RELEASE**

Contact: Kim Zurawski  
kim@mccreadiegroup.com  
202-265-1280

**Investigational Drug Service Software, Vestigo®,  
Selected by Moffitt Cancer Center**

*NCI-designated cancer care leader selects McCreadie Group's Vestigo  
as best-of-breed technology for IDS management.*

**NOVEMBER 17, 2015 – ANN ARBOR, MICH.** – McCreadie Group, Inc., a privately held pharmacy software solutions provider headquartered in Ann Arbor, Mich., is pleased to announce Moffitt Cancer Center's decision to implement its web-based Investigational Drug Service (IDS) product, Vestigo®.

Moffitt Cancer Center is well known for its contributions to the prevention and cure of cancer. Begun in 1978 when H. Lee Moffitt, then a Florida state representative, initiated discussions about constructing a cancer center in Tampa, the Cancer Center overcame considerable challenges before opening to patients in October of 1986.

Moffitt is proud to be one of only 45 National Cancer Institute (NCI)-designated cancer centers in the country, and the only NCI center based in Florida. An NCI designation is the highest recognition of quality cancer research, spanning population, basic and translational sciences.

Launched in 2005, Vestigo eliminates many of the manual steps involved in investigational drug service operations. It has set the industry standard for IDS automation by significantly enhancing efficiencies while helping to ensure that complex protocols are properly managed for consistency, safety and compliance.

Vestigo is used by nearly 50 percent of all NCI-designated cancer centers and 55 percent of the 2015/2016 *U.S. News & World Report's* top-ranked hospitals for cancer.

Vestigo adds accuracy and efficiencies to protocol management, inventory control, dispensing and labeling, billing, accountability reporting, monitor activities and scheduling. It also facilitates compliance to the principles and best practices of IDS, including the Hematology/Oncology Pharmacy Association (HOPA) Best Practice Standards, which apply to any clinical research involving medications. HOPA recommends the use of computer software for investigational medication management.

"Vestigo has been supporting the needs of IDS operations to improve efficiencies and safeguard protocols for almost eleven years now," says Scott McCreadie, PharmD, MBA, founder and president of McCreadie Group. "We are honored to have been selected by Moffitt Cancer Center, an organization whose contributions span science, prevention and clinical research."

- more -

**McCreadie Group, Inc.**

**NEWS RELEASE**

Contact: Kim Zurawski  
kim@mccreadiegroup.com  
202-265-1280

**About McCreadie Group**

The McCreadie Group, Inc. was founded in 2004 to provide software solutions for pharmacy applications in healthcare, research and educational settings. McCreadie Group's goal is to drive improvements in quality, efficiency, safety and compliance in the pharmacy profession by delivering innovative software and consultative support. To learn more about McCreadie Group and its products, visit [www.mccreadiegroup.com](http://www.mccreadiegroup.com).

**# # # #**